Literature DB >> 1517558

Serotonin reuptake inhibitors are the treatment of choice in obsessive compulsive disorder.

N A Fineberg1, T Bullock, D B Montgomery, S A Montgomery.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1517558     DOI： 10.1097/00004850-199206001-00012

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN： 0268-1315            Impact factor:   1.659


× No keyword cloud information.
  4 in total

1.  A novel potential therapeutic avenue for autism: design, synthesis and pharmacophore generation of SSRIs with dual action.

Authors:  Ola M Ghoneim; Diaa A Ibrahim; Ibrahim M El-Deeb; So Ha Lee; Raymond G Booth
Journal:  Bioorg Med Chem Lett       Date:  2011-09-21       Impact factor: 2.823

2.  Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.

Authors:  Stephanie J Klenotich; Mariel P Seiglie; Matthew S McMurray; Jamie D Roitman; Daniel Le Grange; Priya Dugad; Stephanie C Dulawa
Journal:  Neuropsychopharmacology       Date:  2012-03-07       Impact factor: 7.853

Review 3.  Obsessive-complusive disorder: pharmacological treatment.

Authors:  P H Thomsen
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 4.  Treatment of obsessive-compulsive disorder in children and adolescents. A review of the literature.

Authors:  P H Thomsen
Journal:  Eur Child Adolesc Psychiatry       Date:  1996-06       Impact factor: 4.785
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.